GTI-2040 Lorus Therapeutics

Current Opinion in Investigational Drugs

Volumn 2, Issue 10, 2001, Pages 1462-1466

  Orr, R M ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CAPECITABINE; CGP 69846A; ESTRAMUSTINE; FLUOROURACIL; FOMIVIRSEN; GEMCITABINE; GENE EXPRESSION MODULATOR 231; GTI 2040; GTI 2501; HYDROXYUREA; IRINOTECAN; ISIS 2503; ISIS 3521; MG 98; MITOMYCIN C; OBLIMERSEN; PACLITAXEL; UNCLASSIFIED DRUG; VINBLASTINE;

ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; CANCER; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; FATIGUE; HUMAN; KIDNEY TUMOR; NEUTROPENIA; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION; THROMBOCYTOPENIA;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; HUMANS; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0034780895     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey
2. A preclinical pharmacokinetic study of G3139, a phosphorothioate antisense oligodeoxynucleotide to Bcl-2, in Balb/c mice
3. Antisense oligonucleotides inhibitors for the treatment of cancer: 2-Toxicological properties of phosphorothioate oligodeoxynucleotides
4. Lorus Therapeutics files IND application following positive preclinical results of anticancer drug GTI-2040
5. Lorus Therapeutics announces dramatic anti-tumor results for GTI 2040
6. Lorus Therapeutics announces FDA approval to begin clinical trials of anti-cancer drug GTI 2040
7. Lorus Therapeutics receives issued United States patent for invention of key anticancer drugs
8. Lorus Therapeutics' lead anti-cancer drugs reduce tumor growth in mouse models with human prostate cancer cells
9. Findings on Lorus Therapeutics' lead anti-cancer drug presented at Annual Meeting of American Association for Cancer Research
10. Toxicology studies performed in rhesus monkeys with an outstanding antitumor agent that targets the R2 component of ribonucleotide reductase
11. An outstanding antitumor agent that targets the R2 component of human ribonucleotide reductase
12. Lorus Therapeutics Inc: Progress in Lorus Therapeutics' GTI-2040 phase I/II clinical trial of anticancer drug on target to meet company objectives
13. Patent review: Therapeutic applications for antisense oligonucleotides 1999-2000
14. A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM-231) targeting the type 1 protein kinaase A by two hour infusions in patients with refractory solid tumors
15. The mammalian ribonucleotide reductase R2 component cooperates with a variety of oncogenes in mechanisms of cellular transformation
16. Lorus announces intention to enter phase II clinical trials for GTI-2040 with strategic supply alliance
17. Lorus Therapeutics presents anticancer drug GTI-2040 at international oncology meeting in Greece
18. Progress in antisense technology: The end of the beginning
19. A phase I and pharmacokinetic (PK) study of MG98, a human DNA methyltransferase (MeTase) antisense oligonucleotide, given as a P-hour twice weekly (BIW) infusion 3 out of every 4 wks
20. Phase I and pharmacodynamic study of human DNA methyltransferase (MeTase) antisense oligodeoxynucleotide (ODN), MG98, administered as 21-day infusion q4 weekly
21. Potential roles of antisense technology in cancer chemotherapy
22. GTI-2040, an outstanding antisense antitumour agent that targets the R2 component of human ribonucleotide reductase: From the laboratory to the clinic
23. Preview of the American Society for Clinical Oncology 37th Annual Meeting, San Francisco, CA, USA
24. American Society of Clinical Oncology - 37th Annual Meeting (Part II) - Overnight Report Clinical Pharmacology Poster Session, San Francisco, CA, USA
25. Phase I study of GTI-2040 by continuous intravenous infusion (CVI) in patients with advanced cancer
26. Technology evaluation: Fomiversen, Isis Pharmaceuticals Inc/Ciba Vision.
27. Interview: Lorus Therapeutics
28. From RNA to DNA, why so many ribonucleotide reductases?
29. S phase specific expression of mammalian ribonucleotide reductase R1 reductase R2 subunit messenger RNAs
30. Cell cycle-dependent expression of mammalian ribonucleotide reductase-differential regulation of the 2 subunits
31. Cell cycle-dependent regulation of mammalian ribonucleotide reductase - The S phase correlated increase is subunit M2 is regulated by de novo protein synthesis
32. Ribonucleotide reductase-M1 subunit in cellular proliferation, quiescence, and differentiation
33. Controlled protein degradation regulates ribonucleotide reductase activity in proliferating mammalian cells during the normal cell cycle and in response to DNA damage and replication blocks
34. Ribonucleotide reductase R2 component is a novel malignancy determinant that cooperates with activated oncogenes to determine transformation and malignant potential
35. Ph plus CML patients can be grouped into two groups according to CD7 expression on their CD7+ cells both at diagnosis and after treatment with hydroxyurea
36. Improvements in survival and clinical benefit with gemcitabine as first-line therapy with advanced pancreatic cancer: A randomized trial
37. An investigational new drug treatment program for patients with gemcitabine - Results for over 3000 patients with pancreatic carcinoma
38. Lorus therapeutics GTI-2040 prolonges survival rates of mice models with lymphoma in pre-clinical testing
39. Gemcitabine: Progress in the treatment of pancreatic cancer
40. The biology and treatment of chronic myelogenous leukemia
41. Purification of antisense oligonucleotides